Flavoxate | CAS# 15301-69-6

MedKoo Cat#: 317874 | Name: Flavoxate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Flavoxate is an anticholinergic with antimuscarinic effects. Flavoxate binds and inhibits muscarinic receptors, thereby suppressing the micturition reflex and increases urinary bladder capacity by modifying the micturition center in the brain stem.

Chemical Structure

Flavoxate

CAS#15301-69-6 (free base)

Theoretical Analysis

MedKoo Cat#: 317874

Name: Flavoxate

CAS#: 15301-69-6 (free base)

Chemical Formula: C24H25NO4

Exact Mass: 391.1784

Molecular Weight: 391.46

Elemental Analysis: C, 73.64; H, 6.44; N, 3.58; O, 16.35

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

15301-69-6 (free base) 3717-88-2 (HCl)

Synonym

Flavoxate; Flavoxato; Flavossato; Flavoxatum; Urispas; Bladuril; Spasuret; Uronid; Rec-7-0040 free base; DW61 free base; DW 61; DW-61

IUPAC/Chemical Name

2-piperidin-1-ylethyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate

InChi Key

SPIUTQOUKAMGCX-UHFFFAOYSA-N

InChi Code

InChI=1S/C24H25NO4/c1-17-21(26)19-11-8-12-20(23(19)29-22(17)18-9-4-2-5-10-18)24(27)28-16-15-25-13-6-3-7-14-25/h2,4-5,8-12H,3,6-7,13-16H2,1H3

SMILES Code

O=C(C1=CC=CC2=C1OC(C3=CC=CC=C3)=C(C)C2=O)OCCN4CCCCC4

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 391.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Tang HC, Lam WP, Zhang X, Leung PC, Yew DT, Liang W. Short-Term Flavoxate Treatment Alters Detrusor Contractility Characteristics: Renewed Interest in Clinical Use? Low Urin Tract Symptoms. 2015 Sep;7(3):149-54. doi: 10.1111/luts.12063. Epub 2014 Jun 3. PubMed PMID: 26663730. 2: Zor M, Aydur E, Dmochowski RR. Flavoxate in urogynecology: an old drug revisited. Int Urogynecol J. 2015 Jul;26(7):959-66. doi: 10.1007/s00192-014-2585-5. Epub 2014 Dec 6. PubMed PMID: 25480503. 3: Arcaniolo D, Conquy S, Tarcan T. Flavoxate: present and future. Eur Rev Med Pharmacol Sci. 2015;19(5):719-31. Review. PubMed PMID: 25807422. 4: Zaazaa HE, Mohamed AO, Hawwam MA, Abdelkawy M. Spectrofluorimetric determination of 3-methylflavone-8-carboxylic acid, the main active metabolite of flavoxate hydrochloride in human urine. Spectrochim Acta A Mol Biomol Spectrosc. 2015 Jan 5;134:109-13. doi: 10.1016/j.saa.2014.06.058. Epub 2014 Jun 20. PubMed PMID: 25004902. 5: Sugaya K, Nishijima S, Kadekawa K, Ashitomi K, Ueda T, Yamamoto H. Intravenous or local injections of flavoxate in the rostral pontine reticular formation inhibit urinary frequency induced by activation of medial frontal lobe neurons in rats. J Urol. 2014 Oct;192(4):1278-85. doi: 10.1016/j.juro.2014.04.092. Epub 2014 Apr 30. PubMed PMID: 24793729. 6: Moreno Escobosa MC, Cruz Granados S, Moya Quesada MC. Erythema and hand edema due to flavoxate. J Investig Allergol Clin Immunol. 2012;22(5):390-1. PubMed PMID: 23101324. 7: Attimarad M. Simultaneous Determination of Ofloxacin and Flavoxate Hydrochloride by Absorption Ratio and Second Derivative UV Spectrophotometry. J Basic Clin Pharm. 2010 Dec;2(1):53-61. Epub 2011 Feb 15. PubMed PMID: 24826003; PubMed Central PMCID: PMC3979210. 8: Attimarad M. Liquid Chromatographic Determination of Flavoxate HCl in Pharmaceutical Formulation. J Young Pharm. 2010 Jul;2(3):280-3. doi: 10.4103/0975-1483.66787. PubMed PMID: 21042486; PubMed Central PMCID: PMC2964756. 9: Mohammed ZS, Simi ZU, Tariq SM, Ali KR. Bilateral acute angle closure glaucoma in a 50 year old female after oral administration of flavoxate. Br J Clin Pharmacol. 2008 Nov;66(5):726-7. doi: 10.1111/j.1365-2125.2008.03254.x. Epub 2008 Jul 8. PubMed PMID: 18754848; PubMed Central PMCID: PMC2661991. 10: El-Gindy A, Sallam S, Abdel-Salam RA. High performance liquid chromatographic determination of 3-methylflavone-8-carboxylic acid, the main active metabolite of flavoxate hydrochloride in human urine. J Pharm Biomed Anal. 2007 May 9;44(1):274-8. Epub 2007 Feb 6. PubMed PMID: 17349765. 11: Pérez-Hernández N, Morales-Ríos MS, Cerda-García-Rojas CM, Joseph-Nathan P. Conformational evaluation and detailed 1H and 13C NMR assignments of flavoxate, a urinary tract antispasmodic agent. J Pharm Biomed Anal. 2006 May 3;41(2):603-9. Epub 2006 Jan 19. PubMed PMID: 16426792. 12: Tomoda T, Aishima M, Takano N, Nakano T, Seki N, Yonemitsu Y, Sueishi K, Naito S, Ito Y, Teramoto N. The effects of flavoxate hydrochloride on voltage-dependent L-type Ca2+ currents in human urinary bladder. Br J Pharmacol. 2005 Sep;146(1):25-32. PubMed PMID: 15965499; PubMed Central PMCID: PMC1576239. 13: Pikovskaya I. Incorrect assumption regarding the mechanism of action of flavoxate. J Am Geriatr Soc. 2002 Feb;50(2):399; author reply 399. PubMed PMID: 12028232. 14: Sevenoaks M, Gorard DA. Jaundice associated with flavoxate. J R Soc Med. 1999 Nov;92(11):589. PubMed PMID: 10703502; PubMed Central PMCID: PMC1297440. 15: Enomoto U, Ohnishi Y, Kimura M, Kawada A, Ishibashi A. Drug eruption due to flavoxate hydrochloride. Contact Dermatitis. 1999 Jun;40(6):337-8. PubMed PMID: 10385348. 16: Fehrmann-Zumpe P, Karbe K, Blessman G. Using flavoxate as primary medication for patients suffering from urge symptomatology. Int Urogynecol J Pelvic Floor Dysfunct. 1999;10(2):91-5. PubMed PMID: 10384969. 17: Oka M, Kimura Y, Itoh Y, Sasaki Y, Taniguchi N, Ukai Y, Yoshikuni Y, Kimura K. Brain pertussis toxin-sensitive G proteins are involved in the flavoxate hydrochloride-induced suppression of the micturition reflex in rats. Brain Res. 1996 Jul 15;727(1-2):91-8. PubMed PMID: 8842386. 18: Zhang CX, Sun ZP, Ling DK, Zheng JS, Guo J, Li XY. Determination of 3-methylflavone-8-carboxylic acid, the main metabolite of flavoxate, in human urine by capillary electrophoresis with direct injection. J Chromatogr. 1993 Feb 26;612(2):287-94. PubMed PMID: 8468387. 19: Wehnert J, Sage S. [Comparative studies of the effect of mictonorm (propiverin hydrochloride) and Spasuret (flavoxate hydrochloride) on the bladder detrusor muscle]. Z Urol Nephrol. 1989 May;82(5):259-63. German. PubMed PMID: 2665385. 20: Milani R, Scalambrino S, Carrera S, Pezzoli P, Ruffmann R. Flavoxate hydrochloride for urinary urgency after pelvic radiotherapy: comparison of 600 mg versus 1200 mg daily dosages. J Int Med Res. 1988 Jan-Feb;16(1):71-4. PubMed PMID: 3350206.